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Abstract The nuclear receptor CAR, a phenobarbital (PB)-
responsive transcription factor, translocates into the nucleus of
hepatocytes after PB induction. In non-induced mice, CAR
forms a physical complex with heat shock protein 90 (HSP90)
in the cytoplasm. In response to PB induction, protein phospha-
tase 2A is recruited to the CAR:HSP90 complex. This recruit-
ment may lead CAR to translocate into the nucleus, consistent
with the inhibitions of nuclear CAR accumulation in PB-induced
mouse primary hepatocytes by okadaic acid as well as by gel-
danamycin.
* 2003 Federation of European Biochemical Societies. Pub-
lished by Elsevier Science B.V. All rights reserved.
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1. Introduction
The nuclear receptor CAR is a coordinate transcription
factor that regulates the inducible expression of hepatic genes
in response to xenochemical exposures [1^4]. CAR, retained in
the cytoplasm of non-induced mouse livers or mouse primary
hepatocytes, translocates to the nucleus in response to pheno-
barbital (PB) and PB-like inducers [5,6]. Upon translocation,
CAR forms a heterodimer with the retinoid X receptor and
binds to nuclear receptor sites within the PB-responsive en-
hancer module or PBREM that is conserved in various PB-
inducible genes from mouse to human [7,8]. Thus, nuclear
translocation is an initial response of CAR to PB and other
PB-type inducers in liver in vivo. However, the regulatory
mechanism of the nuclear translocation is poorly understood
at the present time.
The roles of signal transduction pathways in the PB induc-
tion mechanism have become increasingly recognized [5,9^13].
Treatment with protein phosphatase inhibitor okadaic acid
(OA) inhibited induction of the CYP2B genes by PB in rat
as well as mouse primary hepatocytes [9,12]. Moreover, OA
repressed the PB-elicited nuclear translocation of CAR in
mouse primary hepatocytes [5]. It is well known that certain
nuclear steroid hormone receptors such as the glucocorticoid
receptor (GR) undergo agonist-dependent nuclear transloca-
tion and OA inhibits this GR nuclear translocation [14,15].
GR forms a large heteromeric complex in the cytoplasm with
heat shock protein 90 (HSP90), 23 kDa protein (p23), and
immunophilin-like protein [16,17]. In addition to these pro-
teins, protein phosphatase 5 (PP5) is a component of the
GR:HSP90 complex [18]. Whether CAR forms a complex
somewhat similar to the GR remains an important question.
Characterization of a cytoplasmic CAR complex may reveal
the mechanism that regulates the nuclear translocation of
CAR and any protein phosphatase that may be involved in
the regulation [5]. Column chromatography, immunoprecipi-
tation, and chemical cross-linking were employed to charac-
terize a CAR complex in the cytosol of mouse livers. Here
we present experimental evidence indicating that CAR exists
as a complex with HSP90 in the cytosolic fractions from
non-induced mouse livers and that protein phosphatase 2A
(PP2A) is recruited to the CAR:HSP90 complex in PB-in-
duced mice. The regulated interaction of CAR with PP2A
provides a new insight into understanding the molecular
mechanisms by which the receptor senses xenochemicals
such as PB, and mediates the transcriptional activation of
hepatic genes.
2. Materials and methods
2.1. Materials
Butyl Sepharose, DEAE Sepharose and Superose 6 HR 10/30 were
obtained from Amersham Pharmacia Biotech (Piscataway, NJ, USA);
OA and geldanamycin (GA) from Calbiochem (San Diego, CA,
USA); 3,3P-dithiobis(sulfosuccinimidyl propionate) (DTSSP) and Im-
munoPure Immobilized Protein A from Pierce (Rockford, IL, USA);
anti-GR, anti-HSP90 and anti-PP2A AK subunit antibodies from San-
ta Cruz Biotechnology (Santa Cruz, CA, USA); anti-HSP90, anti-
PP1, anti-PP5 and anti-PP2A C subunit antibodies from BD Bioscien-
ces Pharmingen (San Diego, CA, USA). Anti-hCAR antibodies were
prepared in our laboratory [19]. A peptide antibody (anti-mCAR-
N20) was produced in rabbits with the N-terminal MTAMLTLET-
MASEEEYGPRNC conjugated with keyhole limpet hemocyanin, and
was puri¢ed using the peptide and SulfoLink kit (Pierce).
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2.2. Animals and primary hepatocytes
Cr1:CD-1(ICR)BR mice (5^7 weeks) were obtained from Charles
River Laboratories (Raleigh, NC, USA). PB (Sigma, St. Louis, MO,
USA) in saline or the saline vehicle was injected intraperitoneally at a
dose of 100 mg/kg of body weight. One hour after injection, the livers
were removed to prepare cytosolic fractions for immunoprecipita-
tion. To prepare cytosol, mouse livers were homogenized in three
volumes of TEGDM bu¡er (20 mM Tris^HCl (pH 7.5), 1 mM
EDTA, 15% glycerol, 1 mM dithiothreitol and 20 mM Na2MoO4)
supplemented with 2 Wg/ml of leupeptin, 2 Wg/ml pepstatin A, and
200 WM phenylmethylsulfonyl£uoride. The homogenate was centri-
fuged at 100 000Ug for 60 min to obtain cytosolic fractions. Mouse
hepatocytes were prepared and cultured as previously described [5].
Hepatocytes were pre-treated with 20 WM of GA, 10 nM of OA or
dimethylsulfoxide for 1 h, washed with culture medium, then treated
with 250 nM of TCPOBOP or dimethylsulfoxide for 8 h. Total RNAs
and nuclear extracts were prepared from primary hepatocytes as de-
scribed earlier [5].
2.3. Column chromatography
Cytosolic fractions prepared from 200 mouse livers were precipi-
tated with 30%-saturated ammonium sulfate and the resulting super-
natant was precipitated with 55%-saturated ammonium sulfate. The
55% precipitate was dissolved in TEGDM bu¡er and applied on a
butyl Sepharose column (150 ml bed volume) in the presence of 0.5 M
of ammonium sulfate. Proteins were eluted by a linear gradient of
ammonium sulfate from 0.5 to 0.0 M. Using Western blot for selec-
tion criterion, CAR-containing fractions were pooled, concentrated
with YM-100 membrane (Millipore), and dialyzed against TEGDM
bu¡er at 4‡C for 16 h. The resulting concentrate was loaded onto a
DEAE Sepharose column (15 ml bed volume) and was eluted by a
linear gradient of NaCl from 0.0 to 0.5 M. After DEAE chromatog-
raphy, CAR-containing fractions were pooled, concentrated, and dia-
lyzed against HEGMS bu¡er (20 mM HEPES-KOH (pH 7.6) bu¡er
containing 1 mM EDTA, 15% glycerol, 100 mM NaCl, and 20 mM
Na2MoO4). For gel ¢ltration, Superose 6 HR 10/30 column was equil-
ibrated with 20 mM Tris^HCl (pH 7.5) containing 1 mM EDTA, 150
mM NaCl, and 20 mM Na2MoO4.
2.4. Analytical methods
Proteins (in HEGMS bu¡er) were cross-linked in the presence of
5 mM DTSSP on ice for 2 h. The reaction was stopped by adding
Tris^HCl bu¡er (pH 7.5) to a ¢nal concentration of 50 mM on ice.
The resulting reaction mixture was brie£y centrifuged and was sub-
jected to further analysis. For immunoprecipitation, protein A resin
was incubated with a speci¢c antibody (anti-CAR or anti-GR) for 1 h
at room temperature, washed with TEGDM bu¡er twice, and incu-
bated with a given protein solution at 4‡C for 12^24 h. Subsequently,
the resin was incubated in SDS^PAGE sample bu¡er at 100‡C
for 10 min to extract proteins. For Western blot analysis, proteins
were separated on a 4^12% gradient polyacrylamide gel (NuPAGE 4^
12% Bis-Tris Gel, Invitrogen, Carlsbad, CA, USA), transferred to
Immobilon-P membrane (Millipore), and visualized using primary
antibodies, horseradish peroxidase-conjugated secondary antibody
(Santa Cruz Biotechnology), and an enhanced chemiluminescence
Western blotting detection reagent (Amersham Pharmacia Biotech).
CYP2B10 mRNA was measured by quantitative real-time PCR using
an ABI Prism 7700 (PE Applied Biosystems) and speci¢c primers as
previously described [5].
3. Results and discussion
GA, a benzoquinone ansamycin, binds to an ATP/ADP
binding site of HSP90 interrupting its chaperoning function
[20,21]. GA is known to inhibit the agonist-dependent nuclear
translocation of the GR and the progesterone receptor [22^
25]. To determine whether GA inhibited PB induction of
Cyp2b10 gene, mouse primary hepatocytes were treated with
GA for 1 h prior to induction by 1,4-bis[2-(3,5-dichloro-
pyridyloxy)]benzene (TCPOBOP). To measure the levels of
CYP2B10 mRNA in the hepatocytes, total hepatic RNA
was subjected to real-time reverse transcription-polymerase
chain reaction (RT-PCR). Pre-treatment with GA resulted
in the profound reduction of the TCPOBOP-induced mRNA,
as observed with OA-pre-treated hepatocytes (Fig. 1A). Thus,
both GA and OA e¡ectively inhibited the induction of
CYP2B10 mRNA by TCPOBOP in the hepatocytes. To in-
vestigate whether GA inhibited the nuclear translocation of
CAR, we performed Western blot analysis on nuclear extracts
that were prepared from TCPOBOP-induced mouse primary
hepatocytes with or without pre-treatment (Fig. 1B). The nu-
clear accumulation of CAR was dramatically reduced by GA
pre-treatment, as also observed with the OA-pre-treated nu-
clear extracts. These results indicate that GA, similar to OA,
inhibits the nuclear translocation of CAR, thus repressing
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Fig. 1. Inhibition by GA and OA of PB induction. RNA and nu-
clear extract were prepared from the mouse primary hepatocytes
treated with various chemicals as described in Section 2. The RNA
samples (1 Wg each) were used for RT-PCR for quantitative mea-
surement of CYP2B10 mRNA, while the nuclear extracts (20 Wg
protein each) were subjected to Western blot analysis to determine
the content of CAR protein. DMSO, dimethylsulfoxide.
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Fig. 2. A: Removal of GR from the CAR-enriched fraction. 80 Wg
of cytosolic fraction prepared from mouse livers (lane 1) and of
55% ammonium sulfate precipitate (lane 2) and 8 Wg of CAR-en-
riched fraction after butyl Sepharose (lane 3) were subjected to
Western blot analysis. B: Elution pro¢les of CAR and HSP90. A
partially puri¢ed fraction after DEAE Sepharose column was sepa-
rated through a Superose 6 column as described in Section 2. 20 Wl
of each 300 Wl fraction and 80 Wg of cytosol prepared from livers
(cyt) was subjected to Western blot analysis. Molecular size stan-
dards used were thyroglobulin (669 kDa), ferritin (440 kDa) and al-
dolase (158 kDa).
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TCPOBOP-induced transcription of the Cyp2b10 gene in he-
patocytes.
Given the indication of HSP90 involvement in the nuclear
translocation of CAR, column chromatography, chemical
cross-linking, and immunoprecipitation were employed to in-
vestigate CAR in the cytosol from non-induced mouse livers.
Ammonium sulfate fractionation concentrated CAR from the
cytosol into the 30^55% precipitates. The precipitate, re-dis-
solved in TEGDM bu¡er, was subjected to sequential butyl
Sepharose chromatography. CAR was highly concentrated in
the fraction from the butyl Sepharose column, while only a
small portion of HSP90 was retained and GR was undetect-
able (Fig. 2A). Subsequently, this fraction was applied on
DEAE Sepharose for further puri¢cation of CAR. Elutes
from the DEAE Sepharose column were pooled for later ex-
periments, designated CAR-enriched solution. First of all, us-
ing the pooled elutes, gel ¢ltration chromatography was per-
formed to measure the molecular size of CAR (Fig. 2B). The
size appeared to be approximately 500 kDa. Moreover, the
co-elution of CAR with HSP90 suggested that they might be
present as a complex.
The CAR-enriched solution was treated with the chemical
cross-linker DTSSP to examine the presence of a CAR:HSP90
complex. 2-Mercaptoethanol (2-ME) can dissociate proteins
that are cross-linked with DTSSP because the disul¢de bond
is sensitive under reducing conditions. Thus, proteins of the
DTSSP-treated solution were electrophoresed on a SDS^poly-
acrylamide gel with or without 2-ME for subsequent Western
blot analysis (Fig. 3A). CAR appeared as a high molecular
weight band (s 200 kDa) under the non-reducing condition
(without 2-ME), while it migrated as a monomer under the
reducing condition (with 2-ME). HSP90 was visualized on the
same Western blot membrane using an anti-HSP90 antibody.
DTSSP cross-linked HSP90 proteins of two di¡erent sizes:
s 200 kDa and 180 kDa. The s 200 kDa bands overlapped,
indicating that they represented a cross-linked complex con-
taining CAR and HSP90. Based on its size, the 180 kDa band
could be the HSP90 homodimer. To obtain further evidence
for the presence of a CAR:HSP90 complex, the CAR-en-
riched solution was incubated with anti-CAR antibody and
the resulting precipitates were subjected to Western blot.
HSP90 was co-precipitated with CAR (Fig. 3B). These results
clearly indicate that CAR forms a complex with HSP90 in the
cytoplasm of non-induced mouse livers.
OA, at a low nM concentration, inhibits preferentially
PP2A, although it may also inhibit the other phosphatases
such as PP1 and PP5. Given the evidence that OA represses
the nuclear translocation of CAR, we examined whether the
CAR:HSP90 complex also contained PP2A by directly pre-
cipitating CAR with anti-mCAR-N20 antibody from the cy-
tosolic fractions extracted from mouse livers and analyzing
the resulting precipitates by Western blots (Fig. 4). The N20
antibody co-precipitated HSP90 from both the non-induced
and PB-induced liver cytosolic fractions. The PP2A C (cata-
lytic) and AK subunits were co-precipitated from only the
cytosols prepared from PB-induced livers, while PP5 was
not detected in the precipitates prepared from either cytosols.
Thus, these results suggest that PP2A, but not PP5, is re-
cruited to the CAR:HSP90 complex in response to PB induc-
tion. Due to experimental limitations, however, the molar
ratio of PP2A to CAR could not be determined. The possi-
bilities that PP2A dissociated during immunoprecipitation
and/or that only a fraction of CAR:HSP90 complexes formed
in PB-treated cytosol remain an important question in further
investigations. The anti-GR antibody co-precipitated HSP90,
PP5, and PP2A from the cytosols prepared from both non-
induced and PB-induced mouse livers (Fig. 4), which agreed
with the presumption that a pool of the GR:HSP90 com-
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Fig. 3. A: Cross-linking with DTSSP: pooled fractions (0.4 Wg pro-
tein) after DEAE Sepharose were incubated with or without DTSSP
as described in Section 2. The DTSSP-treated and -untreated frac-
tions were incubated at 100‡C for 10 min in the presence or absence
of 2-ME and were subjected to Western blot analysis. Cytosol pre-
pared from livers (80 Wg) was also run for analysis. Molecular
weight (BenchMark1 Protein Ladder, Invitrogen) is shown on the
left. The closed arrows indicate CAR:HSP90 cross-link, whereas the
open arrow shows HSP90 homodimer. B: Immunoprecipitation:
pooled fraction (0.4 Wg protein, Input) after DEAE Sepharose was
precipitated with anti-mCAR-N20 antibody or normal rabbit IgG.
Equal volumes of the bound and of the unbound fraction (3 and 10
Wl, respectively) were subjected to Western blot analysis. Cytosol
prepared from livers (80 Wg) was also run for analysis. The symbols
IP and HC denote immunoprecipitation and heavy chain, respec-
tively.
FEBS 27457 15-7-03
K. Yoshinari et al./FEBS Letters 548 (2003) 17^20 19
plexes are always activated due to constant hormonal expo-
sure and therefore are in dynamic nucleocytoplasmic shuttling
in liver. The co-precipitation of HSP90 and PP5 was consis-
tent with the previous ¢ndings in cytoplasm of rat liver [18].
Our present study was the ¢rst to show that the GR:HSP90
complex in cytoplasm of mouse hepatocytes may also contain
PP2A. These results obtained with the GR antibody, in ad-
dition to the lack of precipitating of CAR, HSP90, or the
PPs by normal IgG, provided us with the excellent controls
to substantiate the speci¢c interaction of PP2A with the
CAR:HSP90 complex.
CAR undergoes OA-sensitive nuclear translocation in
mouse primary hepatocytes treated with PB-type inducers
[5]. Our present study reveals that CAR exists as a complex
with HSP90 in the cytoplasm of non-induced mouse livers and
that the CAR:HSP90 complex recruits PP2A in response to
PB induction. Indicatively, PP2A may be required for the
nuclear translocation of CAR and OA might inhibit PP2A
activity to repress this translocation. Whether PP2A recruit-
ment is a prerequisite in CAR nuclear translocation elicited by
other PB-type inducers such as TCPOBOP remains con¢rmed
in future investigations. When it was expressed in mouse liver,
human CAR translocates into the liver nucleus of mice in
response to TCPOBOP [6]. This translocation was also ob-
served in CAR-null mice (unpublished data). Given the fact
that TCPOBOP translocates human CAR but does not bind
to human CAR, CAR nuclear translocation is not initiated by
binding of inducers. Therefore, it is reasonable to speculate
that, acting as a common regulatory step during nuclear
translocation, recruitment of PP2A may occur in response
to various PB-type inducers. However, the molecular mecha-
nism of how the phosphatase regulates nuclear transloca-
tion remains unclear. CAR does not require its ligand-depen-
dent activation function AF2 domain for PB-elicited nuclear
translocation in the mouse liver in vivo and, instead, the
translocation is dictated by the LXXLXXL motif near the
C-terminus of the receptor molecule [6]. Whether CAR is
the target for dephosphorylation is not known at the present
time. Moreover, whether PP2A regulates the activity of the
LXXLXXL motif requires investigation in the future. The
possibility that the CAR:HSP90 complex may contain a yet
unknown component that can be dephosphorylated by PP2A
remains to be explored. Unlike steroid hormones that interact
directly with the receptors to activate them, PB does not bind
to CAR, making the activation mechanism very complex. In
addition, the extremely low expression of CAR in the liver is
problematic when executing experiments. Nevertheless, our
present evidence of a CAR:HSP90 complex and of PP2A
recruitment in response to PB provides the insights into
understanding the PB-elicited nuclear translocation of CAR.
Continuing these investigations may lead us to elucidate a
novel mechanism of drug action and interaction with the ge-
nome.
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Fig. 4. Co-precipitation of PP2A and Hsp90 from the liver cytosols
with CAR antibody. Cytosols prepared from livers (20 mg each) of
the non-induced (C) and of the PB-treated (PB) mice were precipi-
tated with anti-mCAR-N20, anti-GR or normal rabbit IgG. Result-
ing bound proteins were subjected to Western blot analysis.
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